Clinical trials are increasingly executed across sponsors, CROs, and specialized vendors, yet oversight expectations continue to rise as study complexity grows. Many organizations still rely on fragmented workflows, delayed listings, and disconnected review processes that make collaboration difficult and oversight hard to demonstrate.
This session explores how AI-enabled clinical analytics are helping sponsors and CRO partners move toward a continuous oversight model. Attendees will learn how shared, traceable review workflows, AI-assisted analytics, and centralized access to clinical data improve transparency, accelerate decision-making, and strengthen confidence in oversight without disrupting existing roles or workflows. The discussion will focus on practical approaches to operationalizing AI in regulated environments while maintaining transparency, traceability, and human-in-command decision-making.
Key Learning Objectives
- Understand how increasing trial complexity and distributed execution across sponsors and CROs are changing expectations for clinical oversight and collaboration.
- Identify common operational bottlenecks in clinical data review that delay insight, limit transparency, and make oversight difficult to demonstrate.
- Learn practical approaches for applying AI-enabled analytics to support continuous, traceable oversight while maintaining governance and human-in-command decision-making.
- Explore how shared review workflows and centralized access to clinical data can improve collaboration, accelerate decision-making, and strengthen oversight confidence across study partners.
